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	Colorectal cancer development in inflammatory bowel disease begins many years prior to the development of neoplasia because of occult evolution within the inflamed bowel.
	The cycles of wounding and repair characteristic of IBD provide a selective pressure for mutant cells that are able to rapidly heal the mucosa and withstand the inflammatory insult.
	Measuring and modulating the occult evolutionary process offers new avenues for effectively predicting and preventing colorectal cancer in IBD.







Optimising the management of colorectal cancer (CRC) risk in inflammatory bowel disease (IBD) requires a fundamental understanding of the evolutionary process underpinning tumorigenesis. In IBD, clonal evolution begins long before the development of overt neoplasia, and is likely accelerated by the repeated cycles of epithelial wounding and repair that are characteristic of the condition. Here, we review the biological drivers of mutant clone selection in IBD with particular reference to the unique histological architecture of the intestinal epithelium coupled with the inflammatory microenvironment in IBD, and the unique mutation patterns seen in IBD-driven neoplasia when compared to sporadic adenomas and CRC. We discuss how these data can be leveraged as evolutionary-based biomarkers to predict cancer risk, and in turn improve the efficacy of surveillance programs and the management of dysplasia. From a research perspective, the longitudinal surveillance of IBD patients provides an under-exploited opportunity to investigate the biology of the human gastrointestinal tract over space and time. 
Introduction - Clinical Background and Challenges

Inflammatory bowel disease (IBD) is a chronic relapsing-remitting disorder of the gastrointestinal tract, and consists of two main subtypes: Crohn’s disease and ulcerative colitis (UC). The aetiology of IBD is multi-factorial, with the disease arising following incompletely defined environmental triggers in genetically predisposed individuals, and resulting in an aberrant immune-driven inflammatory response towards an altered gut microbiome(1).

IBD incidence rates are increasing worldwide, with a prevalence now approaching 0.5% in the West(2). For patients with longstanding colonic inflammation, colorectal cancer (CRC) is a recognised and feared complication. Studies quantifying the increased CRC risk in IBD have generated variable results reflecting differences in country of origin, study population and disease duration(3)  The first large meta-analysis assessing cancer risk in IBD showed that a CRC risk of  2% 10 years after UC diagnosis, 8% by 20 years, and 18% by 30 years after colitis onset(4). However, more recent studies suggest that CRC rates may in fact be declining(5).

There are important clinical differences between colitis-associated CRC (CA-CRC) arising in patients with IBD compared with sporadic CRC seen in the general population. CA-CRCs tend to affect younger patients(6) (average age of 50-60 in IBD (7,8) vs. 65-75 in the general population), are more likely to be found in the proximal colon in the presence of Crohn’s disease (9) or primary sclerosing cholangitis(10), are more commonly synchronous (15-20% of CA-CRC(11,12) vs. 3-5% of sporadic CRC), and have a higher frequency of mucinous or signet ring cell histology(13).

Patients with longstanding extensive colonic IBD are enrolled into surveillance programmes that aim to detect precursor colitis-associated dysplasia, a premalignant equivalent of sporadic adenomas. In practice, detecting dysplasia at endoscopy can be challenging. These lesions are often flat, with subtle borders that are difficult to appreciate in the presence of concomitant inflammation. They may be readily missed in a background of extensive mucosal scarring and pseudopolyposis. Missed dysplasia may be a contributing factor in the stubbornly high rates of ‘interval’ CA-CRC that develop between scheduled endoscopies(14).

Even when dysplasia is detected, patient management remains fraught with challenges. The diagnosis of IBD-associated dysplasia is confirmed through histological analysis, with defining features including nuclear atypia, mucin depletion, and an irregular crypt architecture with loss of basal-to-luminal epithelial cell maturation(15) and immunohistochemical staining for markers including p53 and β-catenin are sometimes used to complement histological classification(16).  In practice, dysplasia grading suffers from significant inter-observer variability, and can be challenging to differentiate from regenerative epithelium(17). With improved endoscopic imaging, areas of low grade and indefinite dysplasia are now detected in up to 10% of surveillance colonoscopies(18). Some patients are offered more intensive surveillance, while others are offered the option of colectomy, with all the associated risks of major surgery and consequences of life with a stoma. Data from the largest UK surveillance registry data has demonstrated that the 10-year cancer risk from low grade dysplasia is only 30%(11); others have shown that low grade dysplasia regresses in at least half of patients(19) though the mechanism of regression is unclear. Together these findings indicate that the current primary aim of dysplasia identification in surveillance is inadequate as a cancer risk stratification tool. There is a clear clinical need to better understand the molecular aetiology of CA-CRC, which would enable the identification of more efficacious biomarkers of cancer risk.

This review will summarise the evidence supporting the presence of extensive inflammation-driven clonal evolution in IBD long before the development of any clinically apparent neoplasia, and contrast this with our current knowledge of carcinogenesis of sporadic CRC. Finally, we discuss how knowledge of this occult evolutionary process can aid prognostication and ultimately improve the efficacy of IBD cancer surveillance

Clonal Evolution in IBD – The Evidence

Occult evolution leading to colitis-associated cancer

Carcinogenesis is a process of clonal evolution(20–22); cells acquire somatic mutations that alter their phenotype, which may confer them and their progeny a growth and/or survival advantage within their current microenvironmental context, and enable them to persist and clonally expand. With the occurrence of further mutations, there may be additional selection and clonal expansion. In some cases, this eventually results in the development of a malignant phenotype.

In IBD, the clonal evolution of cancer begins long before the development of a frank malignancy. Numerous studies, using a variety of different molecular techniques, have reported extensive genomic and epigenomic alterations in morphologically normal intestinal mucosa (summarised in Table 1). The surprisingly high mutation burden of ostensibly normal IBD epithelium reveals the ‘occult evolution’ that is occurring in the colitic bowel. These mutant clones clearly experience a positive selective pressure (i.e. mutants cells are fitter than non-mutant cells) since they can expand to fill large areas of the intestinal mucosa(23), and in one extreme case the entire colon length(24).

Mutant clones frequently bear mutations in key tumour suppressor genes including TP53 and CDKN2A (p16), and in the proto-oncogene KRAS(23–26). It is remarkable that these cancer-associated mutations do not alone cause neoplastic growth: it may be that these ‘key’ mutations are necessary but not sufficient for tumour growth, or that the phenotypic effects of these mutations is critically modulated by epigenetic and/or microenvironmental constraints present in non-neoplastic mucosa. Nevertheless, the clonal expansion of these cancer-associated mutants provides a genetic foundation for the for the phenomenon of ‘field cancerisation’(27), the preconditioning a large area of histologically normal epithelium to the future development of neoplastic lesions(28) (Figure 1). Field cancerisation likely explains the high frequency of synchronous and metachronous neoplastic lesions in IBD(11,12).  

The inflammatory micro-environment accelerates clonal evolution

The mutation burden in morphologically normal non-IBD colon is not well characterised; nevertheless the limited evidence available to date suggests that the mutation rate is significantly less than in IBD(29,30), and that widespread clonal expansion of mutant cells is rare(31). Consequently, it seems that the colitic bowel is a ‘hot bed’ of somatic clonal evolution. Why is this the case? Our hypothesis that the evolutionary process in IBD is accelerated by longstanding repeated cycles of epithelial wounding and repair that are characteristic of IBD. Mechanistically, IBD-associated inflammation has the potential to mediate clonal evolution by any or all of the following three mechanisms:

(a)	generating a mutagenic pressure,
(b)	providing a selective advantage to those clones able to survive a (cytotoxic) inflammatory insult,
(c)	providing a selective advantage to those clones able to more rapidly re-populate the healing mucosa. 

Dextran sodium sulphate-treated mice offer a unique opportunity to assess flat and polypoid dysplasia in one animal model; both these lesions develop as a consequence of the induced chemical colitis. Here, the severity of inflammation correlates with the propensity to generate IBD-like flat dysplastic lesions: inflammation scores were an order of magnitude higher in colons containing flat dysplasia compared to those with polypoid dysplasia(32). Moreover, administration of 5-aminosalicylates, the mainstay of treatment for UC, had a varying impact on the incidence and progression of dysplastic lesions based on morphology, with fewer flat lesions that were unchanged in size, but the same number of polypoid lesions that were reduced in size(33).

Patient-based studies confirm that inflammation plays a substantial cumulative role in increasing the CRC risk in IBD, with observational studies consistently demonstrate that CA-CRC development risk is closely linked to the extent(34), duration(4) and severity of inflammation(7). Histological studies suggest that neoplastic lesions arise from a field of marked chronic inflammation, telomere shortening, DNA damage and senescence, with “escape from senescence” a key step in the transition from low to high grade dysplasia(35). Therefore, a comprehensive understanding of carcinogenesis in IBD should not be limited to the study of mutation generation and spread via the epithelial crypt stem cell niche, but should also include a concomitant analysis of the inflammatory stromal micro-environment. Therapeutic interventions that modulate cancer risk in IBD must target these aberrant ‘driver’ micro-environmental changes.

The different evolutionary pressures in colitis-associated versus sporadic carcinogenesis offer an explanation for the different pattern of somatic mutations seen in CA-CRC compared to sporadic cancers(36,37). Available data shows that CA-CRCs have increased mutation frequency of various intra- and inter-cellular signalling molecules. The most notable mutations includes IL-16, a chemoattractant cytokine that is overexpressed in IBD in an inflammation dependent manner(38). IL-16 has a potential role in directly mediating inflammation(39), and so we speculate that this gene mutation could provide a survival advantage in the colitic bowel. Another noteworthy mutation is of RADIL, a modulator of Rho signalling in cell migration, that may speculatively provide a selective advantage in mucosal healing(36). 

Mutation signature analysis(40) of CA-CRCs(36) demonstrate novel trinucleotide context changes not seen before in sporadic CRC (an overrepresentation of A:T→C:G transversions at AA dinucleotides), the predominance of C:G→T:A transitions at CG dinucleotides is very much in keeping with accelerated ageing through rapid cell turnover(41) rather than the accumulation of direct genotoxic hits caused by inflammatory associated carcinogens. Indeed, colitic bowels that progress to high grade dysplasia or CA-CRC demonstrate field changes in ostensibly normal epithelium in keeping with accelerated ageing, including telomere shortening(35) and age-related CpG methylation(42).

While TP53 mutations are found at similar frequencies in both sporadic CRC and CA-CRC, TP53 alteration is an early event in CA-CRC that is found in non-tumour and even non-dysplastic mucosa(43). Indeed, there is accumulating evidence supporting the role of TP53 mutations in promoting cell survival and growth(44). Of interest, the increased frequency and early onset of TP53 mutations may provide an additional explanation for the relatively high proportion of flat dysplastic and cancerous lesions seen in IBD: Chang et al(45) have  demonstrated that flat lesions are significantly associated with TP53-/- mice treated with dextran sulphate sodium, whereas polypoid lesions are significantly associated with TP53+/- and TP53+/+ treated mice.

Perhaps most notably, CA-CRCs show a paucity of APC mutations(36,37) compared to sporadic adenomas and CRC, where APC mutations are a common, important and early “gatekeeper” event(46). APC is a key regulator of the canonical Wnt pathway driving β-catenin signalling; disruption of normal APC function is sufficient to constitutively activate this pathway and initiate sporadic adenomas in non-colitic bowel(46,47). The lack of APC mutation in the colitic bowel raises the possibility of IBD-generated inflammation-mediated alteration of underlying Wnt signalling that renders APC mutation dispensable for tumorigenesis. Indeed, immunostaining studies of colonic epithelium confirm high levels of Wnt signalling as demonstrated by increased nuclear to cytoplasmic β-catenin levels in human UC tissue, with levels that are midway between normal non-inflamed epithelium and frank CRC(48), thereby replicating the constitutive canonical Wnt pathway activation of an APC mutation. Secondly, wounding of the intestinal epithelium induces a whole host of canonical and non-canonical Wnt signalling pathways by mesenchymal cells(49).

Aside from these pertinent genomic differences, it is interesting to note that there is also broad similarity between the genomes of CA-CRC and sporadic CRCs.  Both show a high frequency of TP53 alteration and mutations in the oncogenes KRAS, BRAF, PIK3CA, CTNNB1 and the tumour suppressors SMAD4 and FBXW7 at relatively high, albeit slightly different frequencies between the respective cancer types(36,37,50)  Microsatellite instability is also common to a subset of both cancer types(51,52).  Together these data imply some convergence in the outcome of evolutionary processes of sporadic and CA-CRC development – dysregulation of key pathways such as Wnt signalling for and TP53 function appear necessary for tumour formation in the colon irrespective of the prescence or absence of a (prior) inflammatory stimulus.

In addition to native cells of the epithelial layer, immune cells and bacteria migrate up to the crypt as part of IBD pathogenesis, inducing a myriad of inflammatory cytokines and intra-cellular signalling pathways(1) that are beyond the scope of this review. These pathways act directly on non-neoplastic and dysplastic epithelial cells, that can potentially modulate cancer risk.  Animal model studies demonstrate how transcription signalling by NF-κB, the “master regulator of inflammation”(53) that plays a key role in IBD(54), promotes the survival of pre-malignant epithelial clones(55). IBD-mediated inflammation also promotes β-catenin stability through aberrant PI3K-Akt(56,57) and NF-κB(58) signalling to further enhance canonical Wnt activity. Epithelial STAT3 signalling is also upregulated in active IBD(59). Mouse models show that while this pathway helps ameliorate the effects of chemical colitis by reducing epithelial damage and inflammation, it too promotes the survival and progression of pre-malignant epithelial clones(60). Conceivably, non-cell autonomous effects similar to those identified in other systems may also be at play(61).  In this same context, the impact of the altered immune system in IBD on immunosurveillance and editing necessary to limit colorectal cancer initiation and progression warrants further investigation. For example, CA-CRC and dysplastic lesions show a greater infiltration of CD3+ and CD8+ lymphocytes yet significantly less granzyme B expression compared to sporadic CRC, suggesting impaired cytotoxic function(62). 





IBD Cancer Surveillance Programmes – An underutilised repository for the study of human inflammation-driven cancer evolution

We propose that IBD cancer surveillance is an ideal ‘model system’ in which to study inflammation-associated carcinogenesis in vivo in humans; this has received a paucity of attention to date. Multiple biopsies are routinely taken at each surveillance colonoscopy and subjected to histological assessment for inflammation severity and endoscopically-invisible dysplasia. This creates an extensive tissue library of archival specimens reflecting the temporal-spatial clonal evolutionary changes that occur during carcinogenesis. This rich resource can be utilised to better understand the biology of the intestine and how it is subverted during cancer development. The spatial distribution of genetic alterations across surveillance biopsies indicates the order of mutations that led to the current clone composition: a “trunk” or “founder” mutation present in all biopsies arose before a “branch” mutation that is limited to a subset of biopsies. This phylogenetic analysis of multiple biopsies at a single time-point (e.g. from an individual endoscopy) provides a mechanism for inferring the pattern of genetic changes over space and time.

Several studies have used mapping biopsies to analyse the temporal-spatial changes in clonal populations, including the relationship between copy number changes and key gene mutations. In early studies, flow cytometric analysis of UC colonoscopic biopsies specimens taken over an 8-year period(72) showed that aneuploidy can be detected before the onset of dysplasia in at least 10% of patients, with copy number changes becoming more widespread over time in a subset of patients. TP53 gene mutations can also be found in morphologically normal mucosa(43) and correlates strongly with the presence of aneuploidy. TP53 LOH was found more commonly in dysplasia(73), suggesting that it may be a later event. More recently, longitudinal analysis on three Crohn’s patients using targeted sequencing of TP53, KRAS and CDKN2A (p16) reveal that some cancer cases had arisen from a field of mutant clones that expanded well beyond the cancer resection margin and formed many years prior to cancer growth(24). Similarly, large-scale regional clonal expansions were associated with cancer occurrence in a study that used hypermutable non-coding polyguanine tracts as neutral lineage markers to trace clonal expansions across colectomy specimens(74). 

A genome-wide comparative genomic hybridisation array (aCGH) study found that copy number alterations (CNAs) of chromosomal segments are present in most colons with pan-colitis, and are at increased frequency in those with neoplasia, without left or right colon bias(75). Interestingly, this study reported that most CNAs (~85%) were unique to a single biopsy, with significant differences detected in CNA profiles from biopsies as little as 2cm apart, and no shared CNAs between high-grade dysplasia and cancer and the non-dysplastic surrounding mucosa. This finding suggests that genetic field cancerisation does not universally precede cancer development, and instead some patients show focal genetic instability. Consequently, the detection of these different occult evolutionary processes, including selective mutant sweeps and genomic instability, may provide an indicator for CA-CRC development risk.
Mechanisms of clonal expansion in the colitic epithelium
1.5.1 Colonic crypt architecture

The basic functional unit of the colon is the crypt, a finger-like invagination into the underlying lamina propria lined by a single layer of columnar epithelial cells. Under normal conditions, the majority of crypt cells migrate towards the top of the luminal surface approximately one week later, after which they are shed in the lumen(76). Migration out of the crypt base is associated with differentiation into specialised cell types, including absorptive enterocytes and supporting secretory cell lineages(77). These differentiated cells are continuously replenished by a small number of multi-potent stem cells located in the base of each crypt, known as the stem cell niche(78). In the presence of injury to this actively cycling stem cell pool, cells from further up the crypt axis ‘fall’ into the crypt base and re-gain active stem cell properties(79). It is likely that carcinogenic mutations first start accumulating in the long-lived stem cell lineages of the crypt, as the lifespan of non-stem cells is too short for them to acquire the necessary mutations before being shedded. While LGR5+ crypt base stem cells are clearly implicated in APC-driven sporadic CRC and familial adenomatous polyposis(80), the precise stem cell(s) of origin in IBD-driven neoplasia remains undefined.
Stem cell level evolution

Clonal expansion in the colon begins with the progeny of a mutant cell repopulating an entire crypt in a process referred to as monoclonal conversion of the crypt.  Even in the absence of any mutant cells, the stem cells in a crypt are randomly lost and replaced by a neighbouring stem cell lineage in a process called ‘drift’. This eventually results in extinction of all stem cell populations except for those originating from the one ‘lucky’ stem cell clone that repopulates the whole crypt, in a process referred to as ‘niche succession’(81). 

Some mutations generated in IBD will bias the competition between stem cells to make it more likely that the mutant stem cell will go on to repopulate the entire crypt.  In vivo lineage tracing studies of intestinal crypt cells in recombinant mouse models have been used to measure the advantage of tumorigenic mutations. While a wild-type stem cell will replace another wild-type stem cell only 50% of the time in keeping with neutral competition(82,83), a stem cell with a KRAS mutation will replace a wild-type neighbour stem cell in approximately 75% of competitive divisions(83). Interestingly, TP53 mutations confer no significant competitive advantage in a healthy crypt: these mutant cells will replace wild type cells only 50% of the time. However, in the context of chemically induced colitis (via dextran sodium sulphate treatment), TP53 mutation provides a slight but significant increase in the odds of lineage replacement at 58% (83). The differing fate of TP53 mutations in a colitic crypt compared to a non-colitis crypt reflect the unique selective pressures that exist in the inflamed bowel.

In the healthy bowel, tight morphogen gradients generated by cells in and adjacent to the crypt (84) restrict the size of the stem cell niche, keeping stem cell numbers constant(82). The epithelial wounding that is a hallmark of colitis clearly disrupts these signalling gradients. Additionally, a study in transgenic mice shows how inflammation-mediated NF-κB pathway can induce dedifferentiation of non-stem cells , thereby increasing the size of the pool of long-lived cell lineages that can contribute to carcinogenesis(58).  While the precise mechanisms of morphogen gradient disruption is yet to be characterised in human tissue, the altered cellular composition of the supportive peri-cryptal fibroblasts in colitis is a notable example of niche structure alteration(85) that has been associated with IBD neoplastic progression(86). Understanding the altered morphogen gradients in IBD is key to understanding how and why particular mutant cells have an evolutionary advantage in IBD.
Crypt level evolution

Once a mutant clone has repopulated an entire crypt, further clone expansion is possible by crypt fission, the mechanism by which human colonic crypts divide(81). Thus, the initial cell-level evolution within the crypt switches to crypt-level evolution, and therefore it is natural selection of the crypt population that drives field cancerisation. Crypt fission is the main driver of clonal expansion in the human colon(87); indeed, the fission of crypts surrounding a wound is the primary mechanism of epithelial restitution in the intestine(49). Our understanding of the mechanistic drivers of fission is surprisingly lacking(76). 3D-imaging studies suggest a critical role for the placement of stem cells and their supportive niche-providing Paneth cells(88), and mathematical modelling indicates that a plausible mechanism for triggering fission is the exceeding of a “threshold” number of stem cells(89).

Crypt fission as a mechanism for mucosal healing(ref), and the increase in the frequency of crypt fission events in in the IBD bowel is a reflection of the wounding/repair that is characteristic of the disease. Cheng and colleagues found that while less than 1 in 200 crypts in normal human colon are undergoing fission, this rate was increased at least 60 fold in IBD(90). Mutations that increase the rate of crypt fission are likely to be positively selected in the IBD bowel, as these mutants are better able to heal the damaged mucosa. In line with this hypothesis, KRAS mutant crypts, which are common in IBD, are measured to divide 30-fold faster than their wild-type counterparts in the mouse intestine(91), and TP53 mutation is also reported to increase the crypt fission rate(92). It is therefore reasonable to expect that some mutants which undergo significant clonal expansion and populate multiple crypts in the non-neoplastic epithelium achieve this expansion by the acquisition of mutation(s) that positively regulate crypt fission (Figure 1). This selection for mucosal healing rather than neoplasia per se may be the underlying reason for the common occurrence of flat dysplastic lesions in IBD.  Consequently, we believe that assessing the colitic epithelium for clonally expanded mutations offers a ‘natural experiment’ that can be exploited to identify new genes that modulate crypt fission. This novel approach recognises one of the old paradoxes of cancer biology: the overlap between wound healing and carcinogenesis(93).
Other potential mechanisms of clone spread

One intriguing finding from IBD mapping studies is the detection of mutant populations containing the exact same point mutation (single nucleotide variant) or CNA extending across most of the colon length(24,75). While pan-colonic selection pressure could plausibly select for the same altered cellular or crypt functions time and time again through convergent evolution, it is highly unlikely to induce the exact same point mutation, and hence the very large mutant populations observed are likely to be clonal in origin. It is difficult to see how mucosal repopulation by fission of adjacent crypts alone could explain how the same mutation can spread across the entire bowel in a matter of a few years. These findings raise the possibility of hitherto unidentified healing mechanisms in the colitic bowel. Mouse model studies show that free-floating organoids introduced intra-luminally can successfully engraft on to inflamed bowel to generate long-lasting functional crypt populations; stem cell seeding did not occur in the context of a non-inflamed colon(94). In light of the phenotypic elasticity of multiple crypt cell populations and rapid rate of epithelial shedding in active IBD, this raises the intriguing possibility of “long range stem cell migration” by shedding and distant re-engraftment of stem cells. We should emphasise that there is no evidence to date for this speculative healing mechanism in human studies or in IBD animal models. However, there is precedence for this in other model organisms: long distance stem cell migration has been noted to occur between widely separated ovarian follicles in Drosophila(95).
An evolutionary perspective on managing cancer risk in IBD
Predicting cancer risk

There has been great interest in the development of biomarkers of cancer in IBD(96), with DNA aneuploidy(97) and/or TP53 mutations(43,98,99) as the most prominent examples of genetic biomarkers. It is now clear that extensive within-lesion genetic and phenotypic heterogeneity are hallmarks of both carcinogenesis(100) and premalignant pathology(22). Indeed, in the premalignant disease Barrett’s oesophagus, which confers an approximately 30-fold increased risk of developing oesophageal adenocarcinoma(101), sequencing studies suggest that the majority of non-progressor Barrett’s epithelium bear cancer-related mutations in a plethora of different genes. With the exception of TP53, these occur at similar frequencies across non-dysplastic through to high grade dysplasia and even adenocarcinoma tissues(102). In sporadic CRC, large-scale sequencing projects reveal only 7 genes that are recurrently mutated in more than 10% of patients, meaning that the overwhelming majority of mutations were unique to small subsets of patients(50). Collectively, these data indicate that it is improbable that a single gene or small set of genetic changes can effectively assay the vast array of different molecular pathways that lead to cancer(103), and so we consider it unlikely that traditional “candidate-gene” biomarker approaches will yield clinically applicable prognostic biomarkers.  Nevertheless, we note that as the cost of sequencing continues to fall, it well may be possible to cost-effectively sequence a relatively large panel of genes that encompasses all the key pathways involved in CA-CRC development (once these have been identified) – such an approach shows promises in acute myeloid leukaemia(104).

A different approach involves looking for robust prognostic biomarkers from measurements of the underlying evolutionary process itself. The rationale is that while the evolutionary paths may differ between patients, limiting the efficacy of candidate gene based studies, somatic evolution is always subject to the same ‘rules’, as the selective pressures of an inflamed bowel are similar across patients. Therefore, biomarkers based upon measurements of these ‘evolutionary rules’ could have universal applicability.

One example of a candidate ‘evolutionary biomarker’ is clonal diversity. In ecological studies, the level of diversity in a population is a major determinant of its rate of evolution: if there is no diversity, natural selection cannot operate, whereas diverse populations are likely to adapt and evolve quickly. In other words, the diversity of a population is a measure of its evolvability. Translated to IBD, the clonal diversity around the bowel is a potential ‘evolutionary biomarker’ of cancer risk and we note that measuring clonal diversity requires no significant prior knowledge of the precise genetic and epigenetic pathways driving tumorigenesis. To date, there have been no studies using genetic diversity measures for CA-CRC risk, but the principle had previously been applied to Barrett’s oesophagus. Genetic diversity measures were predictors of cancer risk even after controlling for age, Barrett’s segment length, TP53 mutation and aneuploidy status(105), and are robust to the molecular assay used to detect diversity(106). A second approach that also reflects evolvability would be to detect large clonal expansions as a measure of ‘ongoing evolution’. Preliminary studies that attempt to discriminate between progressors and non-progressors  the ability of 4-5 biopsies spaced on average 20cm apart to detect mutant cells derived from an expanded clonal population with shared point mutation(s) makes this a promising avenue to explore(74). Thirdly, changes over time in the clonal composition of the epithelium may also be prognostic, irrespective of what those changes may be, because they are also an indicator of on-going evolution. In Barrett’s oesophagus neoplastic initiation appears abrupt: SNP-array studies suggest that significant discriminating changes in clonal composition occur only 24 months prior to oesophageal adenocarcinoma detection. Finally, analysing changes in immune, mesenchyme, and/or microbiome micro-environmental composition, which form the ‘soil’ for future evolution, and/or their modulation by the epithelial cells themselves(107) offers yet another approach. Concomitant genomic-microenvironmental evolutionary studies can also help answer a “chicken-and-egg” question in CA-CRC: which came first, the altered microenvironment, that predisposes to cancer risk, or the predisposed clones themselves? 
Optimising Screening Intervals

Endoscopic screening intervals (the time between successive endoscopies) could potentially be optimised by an underlying knowledge of the temporal-spatial dynamics of clonal evolution occurring in IBD. The reason for this is straightforward: if we know the minimum time it will take for a cancer to evolve from the current composition of the bowel, we can plan surveillance accordingly. 

Our current knowledge of the rates of clone growth in the colitic bowel is minimal.  Basic questions such as the duration of time required for a clone to undergo expansion substantial enough to be detectable with biopsy and the time required to establish a mutant field remain unanswered.  Moreover, the rate and consistency of mutation accumulation is unknown.  It is our opinion that measuring these fundamental ‘evolutionary parameters’ could have direct clinical relevance.

A practical factor to consider when using IBD surveillance is the fidelity of standard mapping biopsies at reflecting true clonal composition of the entire colon. Routine colonoscopic biopsies contains around 200 crypts(108). Due to the sheer length of the whole colon, even the most intensive IBD mapping biopsy protocols sample less than 1% of the colonic mucosal surface(109). Thus, endoscopy-based studies may result in significant clonal populations being missed, unless clonal patch sizes truly are often large as those detected in some patients by Galandiuk(24) and Lai(75). Understanding the clonal mosaicism of the bowel could help guide ‘optimal’ biopsy protocols.  Moreover, as UC by definition starts in the rectum and extends proximally, we speculate that the rectum is the site where the ‘most’ evolution has occurred and so the evolutionary dynamics in the distal colon may have the most relevance for disease aetiology. Indeed, preliminary evidence raises the possibility that chromosomal instability of the rectal is a proxy marker of cancer risk for the whole large intestine(110). Nevertheless, this approach may not apply for patients with Crohn’s disease and ‘skip lesions’, or for patients with PSC with a propensity to develop right sided colonic cancer due to possible aberrant enterohepatic biliary circulation(111).

Assessing the evolutionary dynamics would allow us to define the window of opportunity for cancer risk prognostication, rationalise colonoscopic biopsy protocols (random vs. segmental vs. endoscopic areas of concern) and determine the appropriate time intervals between endoscopies (Figure 2). To ensure clinical utility, such a biomarker should aim for maximal sensitivity to avoid missed cancer cases.
Managing Neoplastic Lesions

Managing dysplasia remains the most challenging clinical dilemma in IBD surveillance. Differentiating those patients requiring immediate colectomy from those who can be safely managed conservatively remains difficult. Recent consensus guidelines based on dysplasia morphology and endoscopic resectability aim to standardise clinical approach(112). While the majority of patients with low grade dysplasia will never develop cancer, 25% of patients with low grade dysplasia who are advised to undergo colectomy will already have an established cancer in their surgical specimen(11). Even when a cancer is detected at colonoscopy, it is not uncommon for patients to request a segmental resection rather than proctocolectomy, so as to avoid living with a stoma and/or pouch. Such requests go against standard clinical advice: at least one third of patients with a undergoing colectomy for CA-CRC detected at surveillance will have a second synchronous neoplastic region(11). 

Dysplastic lesions offer an ideal opportunity to assess the utility of evolutionary biomarkers by “localising” the site of a mutant field (Figure 2). These lesions and the surrounding mucosa can be assessed for markers of somatic evolution such as the local burden of genomic alteration (or mutational burden), The sizes of clonally expanded patches and the degree of clonal diversity may be able to identify high-risk lesions that are likely to progress to CRC. This is particularly useful for patients with recurrent, “invisible” or non-resectable low grade dysplasia, where evolutionary markers associated with a high risk of cancer development could be used as an indication for colectomy. Furthermore, analysing the remaining mucosa to determine the spatial extent of these high risk changes may allow for the identification of a subset of patients with limited field changes, who could be offered a segmental colectomy that preserves anorectal function.
Optimising treatment to prevent cancer

With inflammation a key driver of CA-CRC risk in clinical and laboratory studies, assessing how therapy modulates occult evolution provides a means to understand how and why drug treatments impact cancer development. Aspirin reduces both (sporadic) CRC incidence(113) and precursor adenoma recurrence(114)(ref), and evidence from Barrett’s oesophagus shows that NSAID use slows the rate of somatic mutation accumulation (115) suggesting an evolutionary mechanism of cancer prevention. Together these data imply that attenuation of inflammation can have profound influence on the carcinogenic process. Nevertheless, while drug treatment in IBD may well modulate clonal evolution of the colitic bowel, similar studies assessing evolution patterns before and after therapy are needed to define and rationalise the most optimal medical intervention strategy.  Since a clear majority of patients undergoing surveillance show some evidence of active inflammation on biopsy(116), it may generate greater clinical impetus towards achieving deep remission(117) in high risk patients, rather than symptomatic relief alone.
Conclusion





Levine, 1991(118)	Cytometry	DNA aneuploidy	N/A	At dysplasia or CRC
Lofberg, 1992(72)	Cytometry	DNA aneuploidy	N/A	Before CRC
Burmer, 1992(73)	Genotyping	TP53 LOH, DNA aneuploidy	N/A	At CRC
Rubin, 1992(97)	Cytometry	DNA aneuploidy	N/A	2.5 years prior to CRC
Brentnall, 1994(43)	Genotyping	TP53 mutation,TP53 LOH	N/A	At CRC
Chaubert, 1994(26)	IHC#, SSCP*	KRAS mutation	N/A	At CRC
Bronner, 1995(119)	IHC	BCL-2 expression	5 crypts to several cm	At CRC
Brentnall, 1996(120)	Genotyping	Microsatellite locus mutations	N/A	At CRC
Willenbucher, 1997(121)	FISH$and CGH¶	CNAs	N/A	At CRC
Holzmann, 1998(25)	Cytometry, single strand conformation polymorphism	KRAS and TP53 mutations, DNA aneuploidy	Up to one third of the colon length	At dysplasia or CRC
Rabinovitch, 1999(110)	FISH	Copy number change at target loci on chromosomes 8, 11, 17 and 18	Changes seen at both near (average 10cm away) and distal (average 50cm away) tissue	At HGD or CRC
Willenbucher, 1999(122)	CGH	Increased Chromosomal instability	Clonal changes seen in some cases in same colon segment	At CRC
Issa, 2001(42)	Methylation	Increased ER, MYOD, CSPG2 and p16 methylation	N/A	At CRC
O’sullivan, 2002(123)	Cytogenetics (telomere fluorescence)	Reduced telomere length	N/A	At CRC
Chen, 2003(124)	PCR-based DNA fingerprinting	CNAs: The degree of genomic instability in non-neoplastic and neoplastic tissue is similar	N/A	At dysplasia or cancer
Yoshida, 2003(125)	Genotyping	Polyclonal TP53 mutations are present in regenerative mucosa and LGD, become monoclonal in HGD and cancer	N/A	At dysplasia or cancer
Matsumoto, 2003(126)	TP53 genotyping and chromosome 17 microsatellite locus instability	Significantly increased across all stages of neoplasia compared to non-IBD normal controls	N/A	At dysplasia or cancer
Sjoqvist, 2005(127)	Cytometry	Increased DNA aneuploidy	Can involve most of the colon and rectum	At CRC. Limited evidence of aneuploidy detectable at penultimate surveillance colonoscopy prior to cancer detection
Salk, 2009(74)	Hypermutable microsatellite locus genotyping (28 loci)	Increased mutation burden and clonal expansion in progressors	Clonal patches up to 50cm long	At dysplasia or cancer
Garrity-Park, 2010(128) 	Methylation	Increased RUNX3,MINT1, and COX-2 methylation	N/A	At CRC
Leedham, 2009(23)	Genotyping	Mutations in APC, TP53, KRAS, 17p LOH	14cm (clonal)	At CRC
Soderlund, 2011(129)	Cytometry	Increased aneuploidy and increased S phase fraction	All patients with extensive aneuploidy subsequently developed neoplasia	Mean 9.2 year patient follow-up
Lai, 2012(75)	CGH¶, BAC∫ array	CNAs	49-161cm	At CRC
Galandiuk, 2012(24)	Genotyping	Mutations in CDKN2A, TP53, KRAS	Pan-colonic (clonal)	4 years prior to CRC
Salk, 2013(130)	Hypermutable microsatellite locus genotyping and telomere length	Increased mutation burden and clonal expansion in progressors	The largest clone involved most of the bowel length	At CRC
Choi, 2015(131)	Cytometry	Aneuploidy of indefinite dysplastic mucosa predictive of progression	N/A	28 month mean follow up of indefinite dysplasia

Table 1: summary of evidence of clonal evolution in IBD (summary of alterations found in non-dysplastic colonic mucosa). #IHC = immunohistochemistry; *SSCP = single strand conformation polymorphism; $FISH = fluorescence in situ hybridisation; ¶CGH = comparative genomic hybridisation; ∫BAC = bacterial artificial chromosome.

Figures
Figure 1. Differences in clonal expansion between normal and inflamed mucosa may explain the accelerated rate of clonal evolution seen in IBD.
(a)	Normal colon. A random mutation generated within a crypt stem cell (first image, in red) results in an advantageous phenotype that eventually results in the extinction of wild type stem cells. Eventually, all cells of that crypt are formed by progeny of this mutant cell (monoclonal conversion of a crypt, third image). These same mutations often accelerate crypt fission (third image), which is the main mechanism for clonal expansion in the intestine (fourth image). 
(b)	IBD. The altered microenvironment generates epithelial cells with different mutant signatures (blue, first image) compared to normal colon. Active disease provides a selective advantage for those cells that can survive  an inflammatory insult (second image). The subsequent healing process selects for those clones that clones that can more rapidly repopulate the mucosa (third image). In this manner, IBD accelerates clonal evolution and expansion (fourth image).

Figure 2. Different potential manifestations of mutant clonal evolution in IBD. Each colour represents a clonal population. The arrow size and colour represent the degree of inflammation (green and small – in remission; red and large – active). Each asterisk represents a biopsy site. 
(a)	Non-Progression. While an occasional localised mutant clone population can be detected, the overall clonal composition of the colon does not change with time.  The lack of mutant clones and little change over time is an evolutionary biomarker of low cancer risk.
(b)	Progressor with clonal expansions. At the start of surveillance, a large (green) clonal population involving most of the left colon is already present, with a more recently formed (yellow) clone arising from this field (left panel). On-going inflammation generates further successive clonal expansions (centre panel). A dysplastic lesion in the rectum, arisen from the red clone, is resected endoscopically. Biopsies of the surrounding mucosa and the left colon confirm that red mutant clone is extensive. This suggests that the patient is at a significant risk of developing recurrent neoplasia (a consequence of field cancerisation), and that endoscopic resection of dysplasia is unlikely to prevent progression. With ongoing significant inflammation, dysplasia recurs in the rectum and a cancer forms more proximally (right panel). In light of the clonal population composition, a proctocolectomy might be considered.  Here, large scale and/or rapid clonal expansion of cancer-associated mutations could be utilised an evolutionary biomarker of high cancer risk.
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